Ironwood Pharma up as FDA approves expanded use of constipation drug

Ironwood Pharmaceuticals

13/06/2023 13:27

** Shares of drugmaker Ironwood Pharmaceuticals  IRWD.O 
rise 1.9% to $11.6 premarket
    ** Co said late on Monday the U.S. FDA has approved co's
drug Linzess as a once-daily treatment for pediatric patients
aged between 6 and 17 years with functional constipation
    ** Linzess is developed and marketed by AbbVie  ABBV.N  and
IRWD in the U.S. The drug is already available since 2012 for
adults with irritable bowel syndrome with constipation
    ** Functional constipation is a chronic condition
characterized by hard, infrequent bowel movements that are often
difficult or painful to pass, affecting 6 million 6-17 years-old
in U.S. - IRWD
    ** The approval is based on data from late-stage study that
showed statistically significant improvement in patient, when
compared to placebo 
    ** Up to Monday's close, stock had fallen ~8% YTD 

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))